Market Closed -
Japan Exchange
02:00:00 2024-05-29 EDT
5-day change
1st Jan Change
1,614
JPY
-0.28%
+5.66%
+14.91%
Santen Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2021
August 05, 2020 at 02:00 am
Santen Pharmaceutical Co., Ltd. provided earnings guidance for the fiscal year ending March 31, 2021. For the period, the company expects revenue to be of JPY 235,000 Million. Operating profit expected to be of JPY 35,000 Million. Net profit for the year expected to be of JPY 23,000 Million. Basic earnings per share expected to be of JPY 58.35.
Santen Pharmaceutical Intends to Buy Back and Cancel up to 38 Billion Yen Worth of Shares
05-10
MT
Santen Pharmaceutical Co., Ltd. announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.
05-09
CI
Santen Pharmaceutical Co., Ltd. Provides Year End Dividend Guidance for the Full Year Ending March 31, 2025
05-09
CI
Santen Pharmaceutical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2024, Payable on June 26, 2024; Provides Dividend Guidance for the End of Second Quarter of 2025
05-09
CI
Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2025
05-09
CI
Santen Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
05-08
CI
Santen Pharmaceutical to Cancel 12 Million Treasury Shares
03-25
MT
Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024
03-25
CI
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.
03-25
CI
Santen Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2023, has closed with 12,571,400 shares, representing 3.38% for ¥16,178.35 million.
03-21
CI
Santen Pharmaceutical's Returns to the Black in Fiscal Nine Months
02-08
MT
Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024
02-08
CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,700 Yen From 1,650 Yen, Keeps at Buy
01-29
MT
Santen Pharmaceutical Further Repurchases Shares for Over 1 Billion Yen
01-07
MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.
01-05
CI
Santen Pharmaceutical Buys Back Nearly 2 Billion Yen of Shares
12-04
MT
Santen Pharmaceutical’s Fiscal H1 EPS Increases to 69.68 Yen as Net Sales Rise 13.1% to 145.81 Billion Yen; Declares Interim Dividend of 16 Yen Per Share, Maintains Forecast
11-08
MT
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024
11-07
CI
Santen Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on November 30, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024
11-07
CI
Santen Pharmaceutical Buys Back 523,400 shares for 772.6 Million Yen in September
23-10-02
MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.
23-10-02
CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,650 Yen From 1,400 Yen, Keeps at Buy
23-09-21
MT
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024
23-09-19
CI
Santen Pharmaceutical Co., Ltd. Provides Dividend Forecasts for Second Quarter of 2024 and the Fiscal Year Ending March 31, 2024
23-08-03
CI
Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024
23-08-03
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.
More about the company
Last Close Price
1,619
JPY
Average target price
1,827
JPY
Spread / Average Target
+12.85%
Consensus
1st Jan change
Capi.
+14.91% 3.75B +38.59% 727B -7.89% 347B +15.66% 319B +0.24% 274B +13.11% 238B +7.08% 204B -6.26% 203B +4.23% 161B -1.70% 160B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
SANTEN PHARMACEUTICAL CO., LTD. 
